This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

- 1. (Previously presented) A method for identifying a compound that modulates T lymphocyte activation, the method comprising the steps of:
- (i) contacting the compound with a TRAC1 polypeptide or a fragment thereof, the polypeptide or fragment thereof encoded by a nucleic acid that hybridizes under stringent conditions to an antisense nucleic acid corresponding to a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO:1; and
- (ii) determining the functional effect of the compound upon the TRAC1 polypeptide.
- 2. (Original) The method of claim 1, wherein the functional effect is measured in vitro.
- 3. (Original) The method of claim 2, wherein the functional effect is a physical effect.
- 4. (Original) The method of claim 2, wherein the functional effect is a chemical effect.
- 5. (Original) The method of claim 4, wherein the functional effect is determined by measuring ligase activity.
- 6. (Original) The method of claim 1, wherein the polypeptide is expressed in a host cell.
- 7. (Original) The method of claim 6, wherein the functional effect is a physical effect.

Appl. No. 09/998,667 Amdt. dated September 15, 2005 Response to Notice of Non-Compliant Amendment

- 8. (Original) The method of claim 6, wherein the functional effect is a chemical or phenotypic effect.
 - 9. (Original) The method of claim 6, wherein the host cell is primary T lymphocyte.
 - 10. (Original) The method of claim 6, wherein the host cell is a cultured T cell.
 - 11. (Original) The method of claim 10, wherein the host cell is a Jurkat cell.
- 12. (Original) The method of claim 6, wherein the chemical or phenotypic effect is determined by measuring CD69 expression, intracellular Ca2+ mobilization, Ca2+ influx, ligase activity, or lymphocyte proliferation.
- 13. (Original) The method of claim 1, wherein modulation is inhibition of T lymphocyte activation.
 - 14. (Original) The method of claim 1, wherein the polypeptide is recombinant.
- 15. (Original) The method of claim 1, wherein the TRAC1 polypeptide comprises an amino acid sequence of SEQ ID NO:1.
- 16. (Original) The method of claim 1, wherein the TRAC1 polypeptide is encoded by a nucleic acid comprising a nucleotide sequence of SEQ ID NO:2.
 - 17. (Original) The method of claim 1, wherein the compound is an antibody.
- 18. (Original) The method of claim 1, wherein the compound is an antisense molecule.
- 19. (Original) The method of claim 1, wherein the compound is a small organic molecule.
 - 20. (Original) The method of claim 1, wherein the compound is a peptide

- 21. (Original) The method of claim 20, wherein the peptide is circular.
- 22. (Previously Presented) A method for identifying a compound that modulates T lymphocyte activation, the method comprising the steps of:
- (i) contacting a T cell comprising a TRAC1 polypeptide or fragment thereof with the compound, the TRAC1 polypeptide or fragment thereof encoded by a nucleic acid that hybridizes under stringent conditions to an antisense nucleic acid corresponding to a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO:1; and
- (ii) determining the chemical or phenotypic effect of the compound upon the cell comprising the TRAC1 polypeptide or fragment thereof, thereby identifying a compound that modulates T lymphocyte activation.
- 23. (Previously Presented) A method for identifying a compound that modulates T lymphocyte activation, the method comprising the steps of:
- (i) contacting the compound with a TRAC1 polypeptide or a fragment thereof, the TRAC1 polypeptide or fragment thereof encoded by a nucleic acid that hybridizes under stringent conditions to an antisense nucleic acid corresponding to a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO:1;
- (ii) determining the physical effect of the compound upon the TRAC1 polypeptide; and
- (iii) determining the chemical or phenotypic effect of the compound upon a cell comprising the TRAC1 polypeptide or fragment thereof, thereby identifying a compound that modulates T lymphocyte activation.
- 24. (Withdrawn) A method for identifying a compound capable of interfering with binding of an TRAC1 polypeptide or fragment thereof, the method comprising the steps of:
- (i) combining an TRAC1 polypeptide or fragment thereof with an E2 ubiquitinconjugating enzyme polypeptide and the compound, wherein the TRAC1 polypeptide or fragment thereof is encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO:1; and

Appl. No. 09/998,667 Amdt. dated September 15, 2005 Response to Notice of Non-Compliant Amendment

- (ii) determining the binding of the TRAC1 polypeptide or fragment thereof to the E2 ubiquitin-conjugating enzyme polypeptide.
- 25. (Withdrawn) The method of claim 24, wherein the TRAC1 polypeptide or fragment thereof has ligase activity.
- 26. (Withdrawn) The method of claim 24, wherein the E2 ubiquitin-conjugating enzyme polypeptide is selected from the group consisting of Ubc5, Ubc7, and Ubc8.
- 27. (Withdrawn) The method of claim 24, wherein the TRAC1 polypeptide or fragment thereof and the E2 ubiquitin-conjugating enzyme polypeptide are combined first.
 - 28. (Withdrawn) The method of claim 24, wherein the reaction is performed in vitro.
- 29. (Withdrawn) The method of claim 24, wherein the TRAC1 polypeptide or fragment thereof and the E2 ubiquitin-conjugating enzyme polypeptide are expressed in a cell.
 - 30. (Withdrawn) The method of claim 29, wherein the cell is a yeast cell.
- 31. (Withdrawn) The method of claim 30, wherein the TRAC1 polypeptide or fragment thereof is fused to a heterologous polypeptide.
- 32. (Withdrawn) The method of claim 24, wherein the binding of the TRAC1 polypeptide or fragment thereof to the E2 ubiquitin-conjugating enzyme polypeptide is determined by measuring reporter gene expression.
- 33. (Withdrawn) An isolated complex comprising a TRAC1 polypeptide or fragment thereof bound to an E2 ubiquitin-conjugating enzyme polypeptide, wherein the TRAC1 polypeptide or fragment thereof is encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO:1.

Appl. No. 09/998,667 Amdt. dated September 15, 2005 Response to Notice of Non-Compliant Amendment

- 34. (Withdrawn) The complex of claim 33, wherein the E2 ubiquitin-conjugating enzyme polypeptide is selected from the group consisting of Ubc5, Ubc7, and Ubc8.
- 35. (Withdrawn) A method of modulating T lymphocyte activation in a subject, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified using the method of claim 1.
 - 36. (Withdrawn) The method of claim 35, wherein the subject is a human.
 - 37. (Withdrawn) The method of claim 35, wherein the compound is an antibody.
- 38. (Withdrawn) The method of claim 35, wherein the compound is an antisense molecule.
- 39. (Withdrawn) The method of claim 35, wherein the compound is a small organic molecule.
 - 40. (Withdrawn) The method of claim 35, wherein the compound is a peptide.
 - 41. (Withdrawn) The method of claim 40, wherein the peptide is circular.
- 42. (Withdrawn) The method of claim 35, wherein the compound inhibits T lymphocyte activation.
- 43. (Withdrawn) A method of modulating T lymphocyte activation in a subject, the method comprising the step of administering to the subject a therapeutically effective amount of a TRAC1 polypeptide, the polypeptide encoded by a nucleic acid that hybridizes under stringent conditions to a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO:1.
- 44. (Withdrawn) The method of claim 43, wherein the TRAC1 polypeptide comprises an amino acid sequence of SEQ ID NO:1.

. Appl. No. 09/998,667 Amdt. dated September 15, 2005 Response to Notice of Non-Compliant Amendment

- 45. (Withdrawn) A method of modulating T lymphocyte activation in a subject, the method comprising the step of administering to the subject a therapeutically effective amount of a nucleic acid encoding a TRAC1 polypeptide, wherein the nucleic acid hybridizes under stringent conditions to a nucleic acid encoding a polypeptide having an amino acid sequence of SEQ ID NO:1.
- 46. (Withdrawn) The method of claim 45, wherein the TRAC1 nucleic acid comprises a nucleotide sequence of SEQ ID NO:2.